Oxaliplatin — CPB 0683 | AETNA Coverage Update

Aetna modified CPB 0683 for oxaliplatin, effective December 6, 2025. Here's what billing teams need to know.

Aetna updated its oxaliplatin coverage policy under CPB 0683, expanding the list of medically necessary indications for J9263 (injection, oxaliplatin, 0.5 mg) billed across chemotherapy administration codes 96401–96450. The revision adds and clarifies 18 covered oncology indications across commercial medical plans. If your oncology or infusion practice bills Aetna for platinum-based chemotherapy, this change directly affects your prior authorization criteria, your ICD-10 coding, and your exposure to claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Oxaliplatin — CPB 0683
Policy Code	CPB 0683
Change Type	Modified
Effective Date	December 6, 2025
Impact Level	High
Specialties Affected	Medical oncology, hematology/oncology, infusion therapy, GI oncology, gynecologic oncology
Key Action	Audit active oxaliplatin authorizations against the updated 18-indication list before billing claims dated on or after December 6, 2025

---

Aetna Oxaliplatin Coverage Criteria and Medical Necessity Requirements 2025

The Aetna oxaliplatin coverage policy under CPB 0683 covers J9263 for 18 specific oncology indications. Every indication outside that list is considered experimental, investigational, or unproven — and claims for those indications may be subject to medical necessity denial.

Medical necessity for initial approval requires that the patient's diagnosis map to one of the 18 approved indications. Medical necessity for continuation of therapy requires no evidence of unacceptable toxicity and no disease progression on the current regimen. That second criterion is the one that bites practices the most — document it at every visit, or your continuation claims are exposed.

This coverage policy applies to Aetna commercial medical plans only. Medicare Advantage and Medicaid managed care plans may have different criteria. If your payer mix includes Aetna MA products, verify which policy governs those members before assuming CPB 0683 applies.

CPB 0683 does not address prior authorization requirements. Confirm your organization's prior authorization obligations directly with Aetna for each plan type before submitting claims on or after December 6, 2025. A mismatch between the authorized diagnosis and the billed ICD-10 code is one of the fastest paths to a medical necessity denial.

Reimbursement for oxaliplatin runs through HCPCS code J9263, billed per 0.5 mg. Your billing team should verify unit calculations before claim submission — underbilling units is money left on the table, and overbilling is a compliance problem.

---

Aetna Oxaliplatin Exclusions and Non-Covered Indications

Aetna's position is clear: any indication not listed in Section I of CPB 0683 is experimental, investigational, or unproven. There is no gray area written into this policy.

A few specific situations are worth flagging. Nasopharyngeal carcinoma is covered — but only as concurrent chemoradiation, and only for members who have a documented contraindication to cisplatin. Bill this indication without that contraindication documented in the record and you have a medical necessity denial risk.

Anal carcinoma coverage is limited to metastatic disease. If your oncologist is treating a patient with non-metastatic anal cancer using oxaliplatin, that claim will not pass Aetna's medical necessity review under this policy. Make sure your ICD-10 coding reflects the metastatic stage, not just the primary site.

The subcutaneous panniculitis-like T-cell lymphoma indication under primary cutaneous lymphomas is narrow. Other cutaneous lymphoma subtypes are not covered under this policy. If you're treating a cutaneous lymphoma patient with oxaliplatin, confirm the specific subtype before billing.

---

Coverage Indications at a Glance

The full policy includes 520 ICD-10-CM codes. The table below shows which indications are covered. For the complete, billable code set, reference CPB 0683 directly — do not build charge capture or authorization forms from this summary alone.

---

Aetna Oxaliplatin Billing Guidelines and Action Items 2025

Copy Action Items

If your practice has a complex mix of hematology and oncology indications billed to Aetna, talk to your compliance officer before December 6, 2025. The breadth of this policy — 18 indications, 520 ICD-10 codes, and 50+ CPT administration codes — means the exposure from a miscoded claim is real.

---

CPT, HCPCS, and ICD-10 Codes for Oxaliplatin Under CPB 0683

HCPCS Code Covered When Selection Criteria Are Met

Code	Type	Description Copy
J9263	HCPCS	Injection, oxaliplatin, 0.5 mg

Chemotherapy Administration CPT Codes (Related to CPB 0683)

These codes support the administration encounter. Coverage for J9263 is the key billing event — these CPT codes document how the drug was delivered.

Other HCPCS Codes Related to CPB 0683

Code	Type	Description Copy
Q0083	HCPCS	Chemotherapy administration
Q0084	HCPCS	Chemotherapy administration
Q0085	HCPCS	Chemotherapy administration

Key ICD-10-CM Diagnosis Codes

The full policy includes 520 ICD-10-CM codes. The ranges below are the only codes confirmed in the source data provided for this article. Do not build charge capture or authorization forms from this partial list. Reference CPB 0683 directly for the complete code set before finalizing your workflow.

Code	Description Copy
C11.0–C11.9	Malignant neoplasm of nasopharynx
C15.3–C15.9	Malignant neoplasm of esophagus
C16.0–C16.8	Malignant neoplasm of stomach (gastric carcinoma)

The full list of 520 ICD-10-CM codes is available in CPB 0683 directly. Review all applicable codes at the Aetna source document before finalizing your charge capture build.

---